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1 INTRODUCTION 
 
 
 
1.1 CARTILAGE BIOLOGY 
 
Cartilage is a specialized avascular connective tissue comprising of only one single type of cell 
called chondrocyte which is sparsely populated in a collagen and proteoglycan rich hydrated 
extracellular matrix (ECM). Based on the biochemical composition and structure of the ECM, the 
mechanical properties and structural characteristics of the tissue, three major types of cartilage (elastic 
cartilage, fibrous cartilage and hyaline cartilage) can be distinguished. 
Elastic cartilage is found in the pinna of the ear, in the walls of the auditory and eustachian 
canals and tubes, as well as in the larynx and in the epiglottis. This type of cartilage with a more 
elastic property maintains tubes-like structures permanently open and provide intermediate mechanical 
stability. Elastic cartilage mostly consists of type II collagen matrix elements and elastic fiber bundles 
(elastin) which manifest in aligned fiber structures. This structural composition provides a tissue 
which is stiff yet elastic. 
Fibrocartilage is most prominently found in areas which require greater tensile strength and 
support such as between intervertebral discs and at sites of tendons or ligaments connected to bone 
tissue. Typically, fibrocartilage is found at locations which are under considerable mechanical stress 
(i.e. tendon and ligaments) but still provides properties which allow flexible body movement. 
Accordingly, fibrocartilage mainly consists of type I collagen fibers which are aligned in thick fiber 
bundles and chondrocytes arranged in parallel rows between these fibers. The fibrous type of cartilage 
is usually associated with a dense connective tissue, namely the hyaline type cartilage which defines 
the third type of cartilage (1). 
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The hyaline type cartilage is the most abundant type of cartilage and is found in the nose, Larynx, 
trachea, bronchi, in the ventral ends of the ribs, and at the articular ends of the long bones. 
Characterized by the arrangement of the chondrocytes in multicellular stacks which prominently 
produce a type II collagen and a proteoglycan rich matrix, the hyaline type of cartilage provides the 
flexible support in nose and ribs but can also sustain mechanical load during body motion as shown at 
the surface of articular joints. This hyaline type of cartilage is lining as a thin layer of deformable, 
load bearing tissue at the bony ends of diarthrodial joints and is more specifically called articular 
cartilage (1). 
1.1.1 Composition and structure of articular cartilage 
 
 The primary function of articular cartilage is the absorption and distribution of forces, generated 
during joint loading and to provide a lubricating tissue surface which prevents the abrading and 
degradation of the joint and the subchondral bone structure during joint motion. Indeed, the articular 
type of hyaline cartilage has to bear and tolerate enormous physical stress and load during its entire 
lifetime. 
Despite the rather primitive composition of articular cartilage, characterized by chondrocytes 
entrapped in hydrated extracellular matrix molecules such as collagen type II, IV and VI, and 
proteoglycan aggregates, the tissue shows unique, highly defined structural organization to maintain 
its mechanical and functional integration. 
Articular cartilage has two different structural characteristics: (i) cartilage zonation (ii) the 
organization of the extracellular matrix. 
(i) The structure and composition of the entire articular cartilage tissue varies according to the 
distance from the tissue surface and reflects its functional role. Four different zones arranged as layers 
horizontally to the tissue surface can be distinguished and are characterized according to the 
extracellular matrix composition and cellular morphology (Figure 1). 
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Figure 1.  Schematic drawing of the general  
structure of human articular cartilage showing  
the zones, regions and relashionship with  
subchondral bone. The insets show the relative  
diameters and organization  of collagen macrofibrils  
in different zones. (Reproduced from Poole CA  
(2); Composition and structure of articular  
cartilage). 
 
 
 
 
 
In the superficial zone the layer of tissue is composed of flattened ellipsoid-shaped chondrocytes 
and a high concentration of thin collagen fibers arranged in parallel to the articular surface (3). In this 
layer the pericellular matrix structure mentioned below can not be found. The thin layer of cells is 
covered with an acellular sheet of collagen fibers (lamina splendes) which functions as a protective 
barrier between the synovial fluid and the cartilage tissue and controls the in- and egress of larger size 
molecules (4). Its rather low permeability regulates the diffusion transport of nutrients and oxygen to 
the underlying cartilage structures. Only within this zone chondrocytes synthesize and secret the 
superficial zone protein lubricin (5, 6) responsible to reduce surface friction during joint motion. The 
specific arrangement of the collagen fibrils which lay in parallel to the joint surface, provides a high 
mechanical stability of the tissue layer and mainly contributes to the tensile stiffness and strength of 
articular cartilage (7-10).  
Below the superficial zone is the midzone where cell density is lower. This has the more typical 
morphologic features of a hyaline cartilage with more rounded cells and an extensive extracellular 
matrix rich in the proteoglycan aggrecan.  The collagen fibers are synthesized at a lower quantity but 
show larger diameter fibrils which are aligned obliquely or randomly to the articular surface and 
describe an intermediate structure between the superficial zone and the adjacent deep zone. 
In the deep zone, the chondrocytes have a round morphology and are arranged in cell columns 
perpendicular to the cartilage surface. The extracellular matrix contains a high content of 
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glycosaminoglycans and large diameter collagen fibers which form arcades perpendicular to the joint 
surface (11). 
The partially calcified zone defines the boundary of cartilage tissue to the subchondral bone. 
This rather thin layer of calcified cartilage with intermediate mechanical properties functions as a 
buffer between the cartilage and bone tissue. The cells have a smaller volume and are partially 
surrounded by calcified cartilage matrix. The chondrocyte in this zone usually persist in a hypertrophic 
cell stage which correlates with the expression of collagen type X. Finally this boundary provides an 
optimal integration to the subchondral bone tissue and prevents vascular invasion. 
(ii) In addition to this zonation, the matrix surrounding the chondrocytes of articular cartilage 
varies in its organization and can be divided in three compartments, such as the pericellular region 
adjacent to the cell body, the territorial region enveloping the pericellular matrix, and the 
interterritorial compartment which defines the space between these cellular regions (Figure 1)(1). 
The pericellular region which is rich in proteoglycan, decorin, aggrecan, collagen type VI, and 
cell membrane associated molecules like anchorin and decorin (12-14) defines a narrow rim of a 
filamentous matrix network which fulfills the functions of the interlink between the chondrocyte cell 
body and the territorial matrix structure. 
The territorial region describes an envelop surrounding the cells or cluster of cells with their 
pericellular matrix. Thin collagen fibrils (most prominently collagen type II) bind to the pericellular 
matrix and form a basket like structure which protects the cell from damage during loading and 
deformation of the cartilage tissue. Moreover these structures may also contribute to transmit 
mechanical signals to the chondrocytes during joint-loading (15, 16). 
The interterritorial region confines the most volume of the articular cartilage tissue and contains 
intermolecular cross linked collagen fibrils (collagen type II), non collagen proteins and aggregates of 
glycoproteins (14). This extracellular matrix composition provides the tissue with its functional 
characteristic to absorb mechanical load. 
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Mechanical environment in mature cartilage 
Chondrocytes and cartilage tissue during joint motion are exposed to body weight load which 
creates a rigorous mechanical environment for articular cartilage tissue such as direct compression, 
shear, and hydrostatic pressure. The function of articular cartilage to undergo tissue deformation is 
dependent on the specific arrangement of macromolecules in the extracellular matrix. Especially the 
organization of collagen fibers into a three dimensional arranged collagen network can balance the 
swelling pressure of the proteoglycan-water “gel” (17, 18). Cartilage is considered as a viscoelastic 
material composed of three principal phases: a solid phase composed of a dense, collagen fibrillar 
network and charged proteoglycan aggregates, a fluid phase of water and an ion phase with ionic 
species for neutralizing the charged matrix components (19, 20). Under physiological condition these 
three phases define an equilibrium where the extension of the proteoglycan-water gel volume is 
restricted by the firm collagen frame (21). The bound water in the cartilage tissue and finally the 
mechanical properties of the cartilage tissue are influenced by the interaction of water with the large, 
negatively charged proteoglycan aggregates (22). The negatively charged proteoglycans mostly driven 
by chondroitin sulphate residues are balanced by a high concentration of cations dissolved in the 
cartilage tissue (23). 
In summary, the mechanical function of articular cartilage tissue bases on the matrix structure 
surrounding each single cell, the arrangement of the extracellular matrix fibres within the single zonal 
compartment and the proportional composition of the different extracellular matrix components. 
1.1.2 Cartilage ontogeny 
 
Articular cartilage as a part of the limb skeleton develops in a well defined and controlled 
multistep differentiation process of cells from the mesenchymal origin (24-26). 
The establishment of the cartilage structure follows precise and distinct patterns of cell 
differentiation and cell rearrangement driven by environmental factors such as cell-cell and cell 
matrix interaction, growth factor and morphogen mediated signaling (27, 28) as well as defined 
biomechanical conditions (29). 
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The steps of development are divided in 3 phases (Figure 2). In the first phase mesenchymal 
precursor cells migrate from the lateral mesoderm towards the presumptive skeletogenic site and 
determine the cartilage anlagen (30). In the second phase, the epithelial-mesenchymal interactions 
results in the mesenchymal condensation. The pre-chondrogenic condensation is a prerequisite for the 
future establishment of the limb skeleton (31) and is associated with an increased cell to cell contact 
which facilitate the intercellular communication and the transfer of small molecules between the cells 
(32). It has been shown that such a high cell density is required to allow chondrogenic development 
(33) and that the level of cell condensation correlates with the stage of chondrogenic development (34, 
35). Additionally, cell-matrix interactions appeared to play an important role in mesenchymal 
condensation (36). For example the integrin mediated binding of chondrocytes to collagen, has been 
shown to be essential for chondrocyte survival (37, 38). Finally, in the third phase, the overt 
differentiation of immature pre-chondrocytes into fully committed chondrocytes is manifested by an 
increased cell proliferation and by the up-regulation of cartilage specific matrix components like 
collagen type IIα1, IX and XI and aggrecan. In the final commitment of the chondrogenic phenotype 
the cells reduce their proliferative activity and maintain the functional integrity of the mature cartilage 
tissue (24-26). 
The initial function of the cartilage during embryonic development is to give stability to the 
embryo and serve as a template for myogenesis and later for neurogenesis. Most of the embryonic 
cartilage is replaced by bone during a process called the endochondral ossification (39, 40). During the 
endochondral ossification, the chondrocytes progress to the hypertrophic phenotype, which is 
characterized by a massive enlargement of the cell, the onset of the expression of type X collagen (41), 
an increased expression and activity of the alkaline phosphatase and the carbonic anhydrase and a 
reduction in the synthesis of the type II collagens and proteoglycan. Protease inhibitors prevent 
vascular invasion are also reduced. Vascularization of the tissue takes place, and most or all of the 
hypertrophic chondrocytes undergo apoptosis followed by their replacement by osteoblasts which in 
turn will deposit bone matrix in the free lacunae. At the cell level, the entire endochondral ossification 
process can be seen as a sequential progression of the three chondrocytic phenotypes: the committed 
mesenchymal cell, the differentiated chondrocyte and the hypertrophic chondrocytes (42).  
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Within these developmental processes growth promoting factors act on the cell and contribute to 
establish a mature cartilage tissue. 
 
 
 
Figure 2.  The three phases of the development of a skeletal element are (from left to right): (i) migration of 
preskeletal cells (green) to the site of future skeletogenesis, which is always associated with an epithelium 
(purple) and epithelial basement membrane (brown); (ii) interactions of those cells with epithelial cell products 
resulting in initiation of a condensation (yellow); (iii) overt differentiation of chondroblasts or osteoblasts 
(blue). Reproduced from Hall and Miyake (30) 
 
 
Soluble growth factors in the cartilage development 
Within the multi step cell differentiation process a number of growth factors and morphogenes 
are involved and essential during chondrocyte maturation and cartilage tissue formation. The most 
prominent growth factors belong to the transforming growth factor (TGF-β) superfamily which are 
responsible for chondrocyte proliferation (TGF-β1), terminal differentiation (TGF-β3; bone 
morphogenic protein; BMP) (43) or to promote cell-cell interaction in the early stage of 
chondrogenesis (BMP) (44). The insulin like growth factor 1 (IGF-1) which belongs to the IGF family 
of peptide hormones (including insulin) regulates many cellular functions during cartilage maturation 
such as induction of chondrocyte differentiation (45) and proliferation (46). In mature cartilage IGF-1 
promotes and maintains the anabolic synthesis of proteoglycan and type II collagen (47) and inhibits 
the nitric oxide-induced de-differentiation of articular chondrocytes (48). Furthermore members of the 
fibroblast growth factor (FGF) family of morphogenes influence processes correlated with cell 
division and chondrocyte proliferation and have been shown to promote chondrocyte proliferation in a 
human growth plate ex vivo culture system (49). 
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Finally, only the combinatorial action of these growth and morphogenic factors specifically 
expressed in selective tissue areas in different developmental phases and at defined concentrations 
establishes the precise structure of the articular cartilage tissue. 
 
Maintenance and aging of articular cartilage 
Once the articular cartilage tissue structure is established, chondrocytes reduce their metabolic 
activity and persist in an anabolic and catabolic equilibrium of the matrix components. Although the 
two major extracellular matrix proteins, collagen type II and aggrecan, have a relatively long turnover 
time span (50), they have to be maintained in a balanced state of production and degradation. The key 
factors to maintain the equilibrium of tissue metabolism are found in the physicochemical 
environment of cartilage tissue such as: (i) mechanical load during joint motion; (ii) growth factor 
responsiveness of chondrocytes; (iii) the balanced molecular composition of the matrix (proportions of 
the matrix components). These factors contribute to the preservation of the functional properties of the 
mature articular cartilage surface. 
After the third decade in human the properties of the weight bearing articular cartilage tissue 
significantly change with progressive age (51, 52). The process of cartilage aging has been shown to 
cause changes in the mechanical properties of articular cartilage (53), in the molecular composition, 
structure and organization of the extracellular matrix (54-56) and in the synthetic and metabolic 
activity of chondrocytes (57, 58). In advanced age individual the number of cells, the size of the 
cartilage tissue and the content of bound water diminish (59). The anabolic activity of chondrocytes 
required for the balance of cartilage tissue matrix homeostasis declines and thus the imbalance of 
matrix turn-over causes the loss of tissue matrix structure. Furthermore, in line with the decreased 
ability of chondrocytes to respond to a variety of extrinsic stimuli (e.g. growth factors) the sensitivity 
to catabolic regulative cytokines is enhanced in age. Moreover the imbalance of the tissue homeostasis 
can be moreover manifested by the increased expression of catabolic mediators such as matrix 
metalloproteinases (60). Finally, these change in the molecular structure of extracellular matrix 
components leads a softening of the cartilage tissue which increase the risk of synovial joint 
degeneration, often provoking the clinical syndrome of osteoarthritis (61). 
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However, not only the reduced tissue function in elderly individuals but also the generally low 
metabolic activity of cartilage tissue in combination might explain the limitation in the self-repair 
function of cartilage with increasing age (62, 63). 
1.1.3 Articular Cartilage defects and self repair 
 
Articular cartilage lesions, caused by trauma, osteochondritis dissecans or as a result of 
instability or abnormal loading are a common cause of disability, often associated with pain, reduction 
of joint mobility and loss of function and can ultimately lead to osteoarthritis. Articular cartilage has a 
very limited intrinsic healing capacity, related to the absence of vascularization and the presence of 
few and very specialize cells with low mitotic activity. According to the size of cartilage tissue 
damage in the cartilage surface, several grades of tissue injury can be distinguished which lead to 
different healing response (64-66).  
In the case of partial thickness defects, the classical self-repair of injured cartilage tissue goes 
through conserved mechanisms of cell and tissue necrosis followed by the proliferation of surviving 
chondrocytes adjacent to the site of the lesion. Although these cells aggregate in clusters and 
demonstrate a temporary increased type II collagen synthesis, in long term the formed tissue shows a 
lost of hyaline like cartilage characteristics. Thus, these chondral lesions remain almost unchanged and 
can proceed towards osteoarthritic diseases (67). 
In the case of full thickness defects, the lesion penetrates to the subchondral bone part gaining 
access to the cells that reside in the bone marrow space including the mesenchymal stem cells located 
therein. The repair response elicited by this type of defect results in the formation of a 
fibrocartilaginous tissue in the defect void. Anyhow, the decreased deposition of extracellular matrix 
components and the formed tissue with fibro-cartilage structures lack the strength, the mechanical 
properties and duration of the original articular cartilage tissue as it has been demonstrated in longer 
time follow-up studies (68, 69). 
In conclusion, the two mechanisms of the spontaneous self healing show limitations in the 
quality and mechanical duration as compared to the native cartilage tissue and can increase the risk of 
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tissue and joint degeneration (61). Therefore, procedures to regenerate the functional properties of the 
cartilage surface are crucial to avoid the progression of secondary joint diseases. 
1.1.4 Treatments for articular cartilage defects 
 
The different strategies to treat cartilage defects vary from more conservative approaches, like 
physiotherapeutic measures or application of pharmaceuticals (i.e. corticosteroids, hyaluoronic acid 
and growth factors) towards more invasive (i.e. surgical) procedures.  
 
Arthroscopic repair procedures 
Arthoscopic lavage and debridement are often used to alleviate joint pain. Lavage involves 
irrigation of the joint during arthroscopy, while debridement is the removal of the damaged tissue from 
the joint. Both of these procedures are routinely used to alleviate joint pain however do not induce 
repair of articular cartilage (70, 71). 
Arthroscopic surgical procedures such as drilling, abrasion or microfracture used to induce 
repair of articular cartilage take advantage of the intrinsic repair response observed upon penetration 
of the subchondral bone in full thickness defects.  These techniques rely upon the formation of a blood 
clot and mesenchymal progenitor cell invasion. However, the clinical outcome is varied, which is due, 
in part, to the unpredictable nature of the repair tissue formed, in addition to the age and activity levels 
of the patient (72-74).  
 
Osteochondral Transfer 
Osteochondral transplantation of autogenic and allogeneic tissue has been widely used to treat 
predominantly large osteochondral defects. Allogeneic material derived from cadaveric donors and it 
is indicated for large post traumatic defects of joints. Beaver et al. (75) reported satisfactory long-term 
results with these grafts, but the logistic of implanting a fresh allograft and the risk of transmitting 
infection reduce the indication for this procedure only to severe cases.  Instead, autologous 
osteochondral graft implantation, involves the removal of cylindrical plugs of osteochondral tissue 
from non load bearing regions of the articular cartilage and their implantation into the prepared full 
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depth defect with press-fit fixation. This procedure is indicated in osteochondral defects of 3 to 5 cm2 
in young patient. It provides the re-establishing of a functional cartilage surface which can-absorb 
body weight load but has limitation in terms of poor tissue integration within the adjacent native 
cartilage tissue. Furthermore, the surgical intervention damages intact host tissue and might enhance 
the donor site morbidity (76, 77). 
Even though such invasive procedures hold promise and showed acceptable results in some 
cases the outcome of these procedures shows generally limitations in terms of quality and 
reproducibility (78). 
 
Cell based cartilage repair techniques 
Given the intrinsic limitations of these techniques, innovative surgical approaches have been 
developed focused at obtaining the regeneration of hyaline cartilage and its functional integration with 
the surrounding tissues, as a means to restore the normal knee function and provide durable outcome. 
Autologous chondrocytes implantation (ACI), first introduced by Brittberg in 1987 (79), as well 
as further improved and reviewed (65, 80, 81) has been proven to be clinically effective to restore the 
tissue structure of large full-thickness focal defects of the femoral condyle (82). This technique 
involves two surgical procedures: an arthroscopic harvesting of a small cartilage biopsy from a non 
weight-bearing area of the knee and the subsequent transplantation of in vitro expanded autologous 
chondrocytes, to defect site beneath a periosteal flap obtained from the tibia in the same surgical 
procedure. A large amount of evidence is currently available in the literature concerning the clinical 
results obtained with ACI indicating that the treatment is associated with improved health outcomes, 
such as pain reduction and improved joint functionality. Despite the promising clinical results obtained 
so far, the use of ACI is associated with a number of limitations essentially correlated with the 
complexity and morbidity of the procedure. While the in vitro expansion step is necessary to obtain 
sufficient cell number it induces well-known variations in biochemical and synthetic properties 
leading to cell de-differentiation and loss of chondrogenic phenotype and therefore the outcome in 
tissue quality is often limited (78, 79). In addition, the ACI technique is associated with a frequent 
occurrence of post operative periost hypertrophy. 
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With the intention to overcome these limitations, in a second generation techniques, such as 
matrix-induced autologous chondrocytes implantation (MACI), or the grafting of tissue engineered 
cartilaginous construct (TE), the cells are cultured in the same manner, but are then seeded directly 
onto a biomimetic scaffold which acts as a carrier for the cells. These approaches offers potential 
advantages, consisting in improved cell retention, the even distribution of cells and easily graft 
handling and earlier post-operative rehabilitation for the patient (83, 84).   
    In addition a tissue engineering approach with further in vitro maturation, before 
implantation, could induce cartilaginous extracellular matrix deposition achieving in principle a 
cartilaginous graft with biomechanical and biochemical properties closer to those of the native 
cartilage (85). The requirements and limitations of such in vitro tissue engineering approaches are 
discussed in the following chapter. 
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1.2 CARTILAGE TISSUE ENGINEERING  
 
 
The term “tissue engineering” was first defined by Langer and Vacanti (85) as “an 
interdisciplinary field of science that applies the principles of engineering and life sciences toward 
the development of biological substitutes that restore, maintain, or improve tissue function or a whole 
organ". In line with the improved investigations, the activities in the field of tissue engineering 
broaded and the term “tissue engineering” required an extended definition which moreover 
emphasizes the "understanding of the principles in tissue growth, which then applied, leads to 
production of functional tissue replacements for clinical use" (86).  
Cartilage tissue engineering techniques have emerged as an innovative field of research with the 
potential to recreate three dimensional cartilaginous structures. Although cells have been cultured or 
grown outside the body for many years, the possibility of growing complex, three-dimensional tissues 
(literally replicating the design and function of human tissue) is a more recent development.  Typically 
this is being attempted through the process of harvesting the patient’s own chondrocytes, expanding 
them, and after seeding them onto a biomaterial scaffold, culturing them possibly under controlled 
conditions in bioreactors allowing them to synthesize cartilaginous matrix (Figure 2).  Successful 
engineering of cartilage grafts which follows a cell-scaffold based approach requires optimized in 
vitro culture condition. The success is dependent on three key elements: i) the selection of a cell 
source, able to produce a new tissue with hyaline like cartilage characteristics; ii) the choice of the 
biomaterial which allow cell seeding and promote the chondrogenic differentiation process; iii) the 
application of bio-inductive molecules supplemented in the culture growth media (i.e. growth factors, 
cytokines, hormones, vitamins, glucose and oxygen) or physical stimuli which enable the cells to 
differentiate and to re-organize a cartilage like matrix structure. 
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The three key elements per se but also approaches combining these parameters are currently 
under investigation and open a broad field of research where only an interdisciplinary approach might 
be able to overcome the current limitations of in vitro chondrocyte differentiation and cartilage tissue 
re-formation (78). In the following sections these requirements will be discussed regarding their 
potential and limitations to successfully engineer functional cartilage tissue grafts. 
a)
b)
c)
d)
e)f)
 
Figure 2.  Representation of a typical articular cartilage lesion approach employing tissue engineered cartilage: 
a) Following a traumatic event, trauma could result in significant lesions to the cartilage surface, b) a biopsy is 
harvested arthroscopically and cells are obtained following a digestion procedure, c) cells are plated and 
expanded in monolayer culture, d) once the required number of cells is reached, cells are seeded onto 
biomaterials (scaffold), e) cell-scaffold constructs are hence cultured in vitro for an appropriate amount of time 
to promote cell redifferentiation and extracellular matrix deposition and finally f) the mature constructs is ready 
to be implanted to treat the wounded cartilage. 
1.2.1 Cell sources to engineer cartilage tissue 
 
Among the different parameters which influence the outcome of in vitro tissue engineering 
procedures, the selection and definition of a convenient cell type or cell source is the first issue to deal 
with. The indispensable demands on cells for cartilage tissue engineering are: (i) not to provoke hostile 
immune reaction (ii) not to induce tumorigenic development and (iii) to integrate within the site of 
insertion in a controlled way. 
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The requirements on these cells to moreover improve the quality of in vitro engineered cartilage 
tissue are: (i) to provide sufficient number of cells from the biopsy site which enables the culture of 
cells at a high cellular density to improve the induction of cartilage development in vitro; (ii) to 
harvest a population of cells which is able to properly recover a chondrogenic phenotype and (iii) to 
harvest the cells from body sites with low donor site morbidity caused by additional surgical 
interventions. 
The use of xenogenic (animals derived) or allogeneic (human derived) cells and tissues could 
provide a source of cells with an almost unlimited availability and with a high accessibility to different 
populations of cells to most simply engineer tissue constructs in vitro. Anyhow, the use of an 
allogeneic or xenogenic cell source is usually correlated with possible adverse immunogenic effects 
(87). 
The most evident choice for a non-immunogenic cell source is the use of autologous cells 
harvested from the patient’s own tissue. These cells provide an optimal source which does not induce 
an immunogenic respond. For the implementation in cartilage tissue engineering the most promising 
attempts have been made by the isolation of bone marrow derived mesenchymal stem cells (progenitor 
from mesenchymal origin) or by the use of chondrocytes from cartilage tissue itself. 
 
Mesenchymal Stem cells 
Stem cells have the “capacity for self-renewal or unlimited self-renewal under controlled 
conditions” and “they retain the potential to differentiate into a variety of more specialized cell types” 
(88). Therefore these are cells with multipotent differentiation capacity (89). There are a number of 
stem-cell sources, such as embryonic stem cells and induced pluripotent stem cells. However, it is the 
adult mesenchymal stem cell (MSC) that is of most interest for articular cartilage repair (90). They 
represent an autologous supply of cells which can be easily harvested from a number of different 
tissues, including bone marrow, adipose tissue, muscle, periosteum and synovium (91). Many studies 
have compared these sources in terms of their chondrogenic ability, with several focusing on 
comparison between adipose tissue and bone marrow, of which bone marrow-derived cells have 
shown superior results (92). Bone marrow derived cells are the most readily available as they can be 
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easily harvested in a relatively non-invasive manner.  They can be extensively expanded in vitro and 
kept in their undifferentiated properties when maintained in appropriate culture condition (93, 94). 
Subsequent culture of MSC in the presence of specific growth factors was shown to induce 
chondrogenic differentiation in three-dimensional micromass culture (95-97), or on polymeric cell 
carrier scaffolds  (98), even so, MSC differentiated towards the chondrogenic lineage were shown to 
express markers specific of hypertrophic chondrocytes (99, 100) thus indicating a potential instability 
of the acquired chondrocytic phenotype. Despite a series of recent studies reporting the use of MSC 
for osteochondral defect repair in different animal models (101-103), the long-term efficacy of bone 
marrow derived MSC and their contribution to the regeneration of hyaline cartilage which does not 
remodel into bone in the long term, still has to be demonstrated. 
Alternatively, allogeneic mesenchymal stem cells represent an option for cartilage repair. They have 
been shown to be immunoprivileged, therefore it is possible to deliver them in vivo without rejection 
(104, 105). They have also been shown to produce cytokines, which may help to modulate the repair 
process in vivo.  Thus far, preclinical trials have been encouraging, but it remains to be seen whether 
this type of cellular therapy may become commonplace in clinical practice. 
 Also embryonic stem cells represent a promising cell source but many ethical issues need to 
be resolved prior to their clinical application. 
 
Chondrocytes 
Brittberg et al (79) published the “original method” of using chondrocytes in suspension under 
a periosteal patch for autologous implantation. Thus, chondrocytes are the cells of choice for all 
current ACI procedures.  
The use of chondrocytes is attractive because these cells have been shown to be able to 
synthesize matrix containing Type II collagen and aggrecan (65). However, chondrocytes are in 
limited supply and they must be multiplied in culture to have an adequate number to support a repair. 
As described in chapter 1.4, following a cartilage biopsy, primary articular chondrocytes can 
be successfully maintained and expanded in monolayer culture (106, 107). The application of different 
growth factors during the monolayer culture phase enables chondrocytes to proliferate, while they 
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progressively lose their typical differentiated phenotype and appear fibroblastic (108). However, it has 
been shown that while the exposure of chondrocytes to a variety of growth factors (i.e. TGFβ-1; 
bFGF-2) enhance the de-differentiation of chondrocytes, can additionally improve the capacity to re-
gain a differentiated phenotype during subsequent culture in a permissive chondrogenic environment 
(109). Beside the treatment of the cells with soluble chondrogenic inducer the maintenance of the cells 
in a 3-dimensional environment at a high cellular density during the phase of chondrogenic re-
differentiation can additionally promote the differentiation process (110). 
Nevertheless, considering the implementation of chondrocytes harvested from adult 
individuals in cartilage engineering approaches, the resulting tissue quality shows limitations in terms 
of donor variability which might be influenced by the clinical background, the disease history or the 
age of the individual. In particular, the age of the individual, significantly reduces the capacity of the 
ex vivo cultured chondrocytes to respond to growth stimulation and thus the quality of the cartilage 
tissue produced from cells of elderly donors could be inferior (111, 112). 
The critical issues associated with the use of autologous articular chondrocytes are: the 
acquirement of the biopsy from the individual causing morbidity at the donor site and the following 
small number of available cells. In particular, the harvesting of a cartilage biopsy in the joint 
represents an additional injury to the cartilage surface, and might be detrimental to the surrounding 
healthy articular cartilage (113). To circumvent this problem an alternative approach would be based 
on the use of chondrocytes obtained from non-articular cartilage tissues. For instance, biopsies of nasal 
or ear cartilage can be harvested by a less invasive procedure than excising tissue from distinct areas 
of the joint. The potency of morbidity is also reduced by the fact that the donor site (ear and nose) is 
not subjected to high levels of physical forces, as in the joint. Various studies have been shown that 
chondrocytes derived from human nasal septum or ear cartilage proliferate and generate cartilaginous 
tissue after monolayer expansion with similar or superior capacity to those derived from articular 
cartilage (114-116). However, to demonstrate whether the tissue generated by non-articular 
chondrocytes is adequate for articular cartilage tissue repair, extensive data from in vivo orthotopic 
experimental studies and from in vitro loaded models will be needed. 
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 Both chondrocytes and mesenchymal stem cells are troubled with fibroblastic de-
differentiation and terminal differentiation to a hypertrophic phenotype in vivo. It is therefore likely 
that these cells types will require some degree of modulation to be used successfully. This may be 
provided by the use of specific biomaterials (scaffolds) or by the addition of media supplements 
(growth factors). 
1.2.2 Scaffolds for tissue generation 
 
The purpose of using biomaterial scaffolds for tissue-engineered constructs is to mimic the 3-
dimensional environment of the extracellular matrix, provide structural support to the regenerate and 
surrounding tissues, and provide an increased surface area to volume ratio for cellular migration, 
adhesion and differentiation (117). 
 A large number of scaffold designs and concepts were tested experimentally, in animal models 
and received the approval in clinical applications (118). 
An ideal scaffold material or architecture must provide the following characteristics: (i) bio-
degradable with a controlled degradation and absorption rate which allows tissue in-growth; (ii) 
biocompatible and not provoke a hostile immune response; (iii) a three-dimensional structure with 
defined porosity and interconnectivity to allow cell invasion, tissue growth and transport of nutrients 
and metabolic waste; (iv) mechanical stability for in vitro handling and subsequent implantation 
within surgical procedures; (v) and provide a suitable surface chemistry or the ability to absorb 
proteins to improve chondrocyte attachment, proliferation, or differentiation and thus to promote and 
support tissue specific development (118, 119). 
The two most commonly used solid scaffold architectures reported in the literature are porous 
sponges and non-woven fiber meshes (120). There are several biomaterial options used for articular 
cartilage tissue engineering, which can be natural or synthetic (121). 
Scaffolds based on natural biopolymeric compounds mimic and resemble the natural cartilage 
environment. Further they can be subdivided into protein-based matrices such as collagen and fibrin 
and carbohydrate-based matrices such as alginate, agarose, chitosan and hyaluronan (122). The 
presentation of bioactive surface structures can induce signals to the entrapped chondrocytes and 
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potentially stimulate the chondrogenic differentiation process which leads to the cartilage tissue 
neogenesis (123). 
Various synthetic polymer scaffold materials have been validated in cartilage tissue engineering 
such as polylactic- or polyglycolic acids (124-126), polycaprolactones, polycarbonates or co-polymer 
containing ethylene-terephthalate (127, 128). In contrast to the advantage to provide initial mechanical 
stability, non-immunogenicity and bio-resorbability these scaffold polymers have been shown to 
potentially provoke adverse cytotoxic effects due to the release of acidic products (129). Moreover 
synthetic polymers per se would not have biological properties to induce cartilage tissue regeneration. 
1.2.3 Media supplements and culture environment 
 
Soluble mediators are mostly involved during the event of cartilage growth, metabolism and 
development, such as in the mesodermal differentiation of the cartilaginous skeleton in the embryo, 
the process of endochondral bone formation and the onset of articular cartilage “repair” (25). As a 
common basis of various approaches considered for cell-based engineering of cartilage tissue, it is 
known that during the in vitro culture of chondrogenic cells, specific growth factors, cytokines, 
hormones or enzymatic co-factors (e.g. vitamins) can enhance cell proliferation, migration or cell 
differentiation, and in consequence allow to obtain sufficient cells with the potency to re-induce 
cartilaginous tissue structures. 
In general, growth factors and cytokines are cell-secreted molecules and when bound to cell 
membrane receptors can induce intracellular signaling pathways which lead to cell adhesion, 
proliferation or promote cell differentiation, by the up or down regulation of target genes. 
As compared to the morphogenic action in vivo, several growth factors and mitogens are applied 
in in vitro tissue engineering approaches.  
Basic Fibroblast growth factor (bFGF) within the FGF family is the most widely investigated in 
articular cartilage repair. It is stored bound to heparin sulphate proteoglycan in the extracellular 
matrix. It’s an important mitogen that stimulates RNA and DNA synthesis in chondrocytes (130). 
Many in vitro studies have shown that FGF plays a key role in chondrocytes proliferation (130), 
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promotes the de-differentiation process of primary chondrocyte in monolayer culture (131) and 
prevents chondrocytes from terminal differentiation (132).  
Transforming growth factor-β (TGF-β) is a member of the TGF superfamily, which also 
includes bone morphogenetic proteins (BMPs). It is secreted in an inactive form, bound to a latency-
associated peptide from which it dissociates before becoming active and binding to its target receptor 
(133). Growth media supplementation with TGF-β induces chondrogenic differentiation as shown in a 
pre-chondrogenic cell line (134) or in MSC micromass pellet culture (99), and has been reported to 
promote cell proliferation and to up-regulate aggrecan and type II collagen when applied 
synergistically with insulin or insulin like growth factor-1 (IGF-I) in chondrocyte alginate culture 
(135).  
Platelet-derived growth factor (PDGF) is a known chemo-attractant, stimulating macrophages 
and fibroblasts during healing. It is stored in platelets; hence it was recognized as a key growth factor 
in the microfracture technique attracting cells to the defect site. Not only it is a chemo-attractant, in 
vitro studies have also showed it to have an impact on chondrocytes and mesenchymal stem cell 
differentiation, enhancing matrix production and preventing the progression toward endochondral 
maturation (136-138). 
IGF-I is the main anabolic growth factor of articular cartilage. It has been shown to increase 
proteoglycan and collagen type II synthesis as well as provide chondrocyte phenotypic stability. It is 
stored in the extracellular matrix, bound to proteoglycans via IGF-1 binding proteins. It’s likely that 
the interaction between it and the binding protein regulate its activity, as an increase in catabolic 
activity causes proteolysis of these proteins, thereby modulating its release (139). 
Indeed, there are evidences that the combination of several specific growth factors during the 
phases of chondrocyte expansion and subsequent 3D micro-mass culture can have additive effects on 
the cell proliferation or chondrocyte re-differentiation process (140). 
Moreover, historically, monolayer expansion of chondrocytes is supplemented with Fetal Calf 
Serum (FCS) to support attachment and proliferation (141, 142). 
However, the use of animal serum for the generation of grafts for clinical use should be 
seriously considered since such supplements carry the remote possibility of prion or viral transmission 
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and of immune reaction against animal proteins. Substitution of animal serum with autologous serum 
would address these issues and bring human cartilage engineering nearer to a safe clinical application. 
Previous studies comparing chondrocytes growth with human serum and FCS generally reported 
superior proliferation rate of chondrocytes in human serum (143-147) and also a reduced variability 
due to the donor age of the patient (147) . 
To re-establish a proper matrix structure during the re-differentiation process in 3-dimensional 
chondrocyte culture, enzymatic co-factors can additionally be supplemented. For instance, ascorbic 
acid known as a co-factor for proline and lysine hydroxylase is required for the assembly and 
stabilization of collagen fibrils (148). 
Therefore, in this work we evaluated how the addition to the culture medium of specific growth 
factors (TGFβ-1/FGF-2/PDGF) during monolayer expansion can modulate the proliferation of human 
articular chondrocytes seeded at different cell density and in presence of reduced percentage of Human 
Serum. Moreover we assessed the ability of expanded articular chondrocytes under different 
conditions (different cell seeding density; percentage of Human Serum; monolayer vs 3D expansion), 
to re-gain a chondrogenic cell phenotype during the phase of re-differentiation (exposed to TGFβ-1/ 
insulin/ ascorbic acid) in 3 dimensional cell culture system (i.e. micro mass pellet and collagen type II 
scaffolds). 
1.2.4 In vitro culture of chondrocytes: expansion strategies 
 
Chondrocyte-based cartilage repair techniques, including the mentioned ACI, require that 
autologous articular chondrocytes isolated from a small biopsy are efficiently expanded prior to being 
grafted in the defect. However, this approach is limited by the difficulty of obtaining sufficient 
autologous chondrocytes. Finding conditions that permit fast amplification of chondrocytes while 
maintaining their capacity to generate cartilaginous tissue is an objective of different research groups. 
The main obstacle for an efficient propagation of chondrocytes derived from the fact that the cell in 
vitro expansion is intrinsically associated with cellular de-differentiation and reduced ability to re-
differentiate.  
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De-differentiation occurs when chondrocytes are cultured under conditions allowing them to 
attach and spread on a two-dimensional surface. In this environment the spherical phenotype is 
gradually lost and the cells acquire an elongated fibroblast-like morphology.  
These morphologic alterations are accompanied by profound biochemical changes, as indicated 
by the reduction or total loss of synthesis of aggrecan and type II, IX and XI collagen (cartilage-
specific proteins) and the increase in synthesis of versican and type I, III and V collagen (proteins 
associated with an undifferentiated mesenchymal cell phenotype).  
To overcome the limitation of a low initial number of cells and dedifferentiation, various 
studies have been performed in which chondrocytes are multiplied in monolayer cultures to increase 
the number of cells and then transferred into an environment supporting a spherical morphology; 
however their original phenotype is not fully re-acquired (108, 149-151). 
In an effort to overcome this problem different strategies have been proposed to expand 
chondrocytes under conditions maintaining their original phenotype. These include the culture of 
chondrocytes within 3D gels, sponges or meshes, encapsulated in alginate beads or at the surface of 
microcarrier beads (152-154). The culture techniques allow chondrocytes to remain round in shape 
and to continue the expression of cartilage-specific genes, but are limited in the extent of proliferation 
achieved (155). 
One alternative approach to obtain a large number of chondrocytes capable to generate 
cartilaginous tissues, in contrast to the above described strategy, consists in keeping cells in a more 
‘plastic’ state, thus enhancing their ability to re-differentiate. In particular, the growth factor 
combination transforming growth factor beta-1, fibroblast growth factor-2 and platelet-derived growth 
factor-BB (TFP) was shown to increase cell proliferation rate, accelerate the process of cell de-
differentiation, and to enhance the re-differentiation capacity of the expanded cells (109). 
Another approach to enhance the post-expansion differentiation capacity of chondrocytes is 
based on the coating of cell culture dishes with specific substrates. In these regards, Barbero et al. 
(156) found that chondrocytes expanded in type II collagen exhibited higher capacity to generate 
cartilaginous tissues as compared to cells expanded in plastic culture dishes.  
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1.2.5 Redifferentiation and implantation 
 
During the monolayer expansion, the chondrocytes dedifferentiate and gradually lose their 
phenotype. However the feasibility to engineer cartilage tissue starting from expanded chondrocytes is 
based on the fact that, at least to some extent, the differentiation process may be reversed when cells 
are transferred into three dimensional environments (157) under appropriate culture conditions (140, 
147). The ability of redifferentiate is particularly important when the cell-constructs are going to be 
transplanted back into the patient. 
After implantation, engineered tissue unlike native tissue must continue to grow and remodel in a 
chemical environment that is likely to contain potent catabolic mediators stemming from inflammatory 
responses resulting from the disease or the surgical intervention it-self.  
During an inflammatory response, cartilage remodeling process is initiated and cytokines such as 
Interleukin (IL)-1 and Tumor Necrosis Factor (TNF)-α, are produced in response by resident cells and 
infiltrating inflammatory cells (chondrocytes, monocytes, neutrophils). In particular, IL-1 (α and β) is 
a pro-inflammatory cytokine that plays important role in normal physiology of cartilage tissue, 
including stimulation of the turnover of extracelllular matrix. IL-1 isoforms have  been shown to have 
harmful effects on chondrocytes: they (i) inhibit the synthesis of the major physiological inhibitors of 
pro-degradative enzymes  (158), (ii) stimulate the production of prostaglandins, free radicals and NO 
(159), (iii) inhibit the synthesis of matrix components such as type II collagen and proteoglycans (160-
163), (iv) inhibit the chondrocyte differentiation- phenotype by suppressing the expression of Sox-9 
(160, 164), (v) inhibit the chondrocytes proliferation and induce cell death (164).  
These post-operative inflammatory responses have particular relevance in the context of cell based-
cartilage repair, considering that therapeutic cell preparations (single cell suspension, cell-seeded 
matrixes or cartilaginous tissues) once grafted in the joint defect will become exposed to a 
biochemical environment rich in catabolic mediators and could have long-lasting detrimental effects 
(165). 
It’s therefore important to define the appropriate stage of maturation for cell-based constructs and the 
consequential state of cell redifferentiation at which the chondrocytes result less susceptible to such 
mediators guaranteeing superior clinical outcome. 
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1.2.6 Automated tissue engineering system for clinical application 
 
A bioreactor is an apparatus in which biological and biochemical processes develop under finely 
designed environmental and operating conditions such as pH, temperature, pressure, nutrient supply, 
waste removal and biomechanical stimuli (166). 
 Recently, bioreactor culture systems have been applied to the tissue engineering field, providing 
reliable models to study tissue biology under controlled experimental conditions. Moreover, the use of 
bioreactors introducing high level of control, reproducibility and automation can be applied to the 
manufacturing process of tissue engineered products for clinical applications.  
Currently, in the case of the manufacturing process for cultured tissues aiming at autologous 
transplantation, such as autologous chondrocytes implantation (ACI), a minimum of biopsies is 
harvested from patients.  The isolated cells after shipment to special GMP production facilities are 
subjected to ex vivo expansion in a series of monolayer cultures. After the cells are expanded 
sufficiently, cells or three-dimensional grafts are returned to the hospital for implantation. Obviously, 
the resulting process of manufacturing is burdened by limitations such as the lack of standardization 
with the risk of biological contamination due to the numerous manual handling steps. Additionally, 
high cost due to the implementation of special room facilities in compliance with Good Manufacturing 
Practice (GMP) requirements are associated with manufacturing. Therefore, the application of cell-
based tissue engineering approaches in the routine clinical practice critically depends on the 
development of innovative bioreactor systems. 
An ideal bioreactor would be a single closed and automated system in which starting from a 
patient’s biopsy, are performed all the different processing phases: cell isolation, expansion, seeding 
on scaffold and differentiation. 
A controlled closed bioreactor system would therefore facilitate the streamlining and automation 
of the numerous labor-intensive steps involved in the in vitro engineering of 3D cartilage tissue in a 
manner that is reproducible, safe, clinically effective as well as economically acceptable and cost-
effective (167). 
One example is the Autologous Clinical Tissue Engineering System (ACTES), under 
development by Millenium Biologix (www.millenium-biologix.com), is a closed bioreactor system 
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aimed at fully automating the processes cartilage biopsy digestion, chondrocytes expansion and cell 
resuspension. However associated to a bioreactor system like ACTES, there are several constraints 
such as a fixed expansion surface, the possibility of a single passage and the requirement to yield a 
minimum amount of cells (12 Millions) and the necessity to reduce the percentage of autologous 
serum.  
 We aimed our study to define suitable operating conditions for systems like ACTES.  In 
particular we aimed our study at determining whether a clinical relevant number (≥12 millions) of 
human articular chondrocytes can be generated in 1 passage starting from variable initial seeding 
densities and using low percentages of human serum, assuming a defined culture surface, currently in 
use in the ACTES system. 
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1.3 AIMS OF THE THESIS 
 
Cartilage lesions resulting from trauma or degenerative diseases are one of the major factors leading to 
joint disease and disability. Articular cartilage being an avascular tissue has limited capacity for self 
repair.  
To overcome these limitations, tissue engineering techniques have emerged as an innovative field of 
research with the potential to recreate three dimensional cartilaginous tissues.  
Such approach generally rely on the expansion of a limited population of chondrocytes derived from a 
small cartilage biopsy, intrinsically associated with cellular de-differentiation (108), and on the ability 
of the expanded cells to efficiently and reproducibly re-differentiate and generate cartilaginous tissue. 
The objective of my research was to study different clinically relevant aspects of the biology of human 
articular chondrocytes, related to different phases in the process of engineering of a functional 
cartilage tissue (Figure 4). In particular, my thesis was aimed at determining:  
 
 
- whether the supplementation of growth factors enhancing chondrocyte proliferation and re-
differentiation capacity allows a reproducible and efficient clinical-scale expansion of human articular 
chondrocytes (HAC) starting from variable initial seeding densities and using low percentages of 
human serum (Study 1; Francioli et al., Tissue Eng (2007)); 
 
 
- whether the quality of cartilaginous tissues generated by HAC on three-dimensional biomimetic 
scaffolds can be enhanced by direct expansion on the scaffold, as compared to standard growth on 
plastic, or by increasing cell seeding density (Study 2; Francioli et al., Tissue Eng (submitted)); 
 
- how the extent of maturation of HAC-based cartilaginous tissues modulates the profile of chemokine 
production and the inflammatory/catabolic response to IL-1β (Study 3; Francioli et al., Clin Orthop 
Relat Res (in preparation for submission)). 
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2 PAPERS  
 
2.1 PAPER I: Growth Factors for Clinical-Scale Expansion of 
Human Articular Chondrocytes: relevance for Automated 
Bioreactor System 
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2.2 PAPER II: Effect of three-dimensional expansion and cell 
seeding density on the cartilage-forming capacity of human 
articular chondrocytes in type II collagen sponges 
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2.3 PAPER III: Production of cytokines and response to IL-1β by 
human articular chondrocytes at different stages of tissue 
maturation 
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3 SUMMARY  
 
 
Regenerative medicine holds great promise for the reconstitution of damaged tissues and organs. 
Treatment for articular cartilage injuries is a prime target for regenerative techniques, as spontaneous 
healing is poor. 
  Among the many surgical options for the treatment of such lesions, implantation of autologous 
chondrocytes is gaining increasing popularity, especially for critically sized defects (79, 91). These 
procedures include autologous cartilage implantation (ACI) (65, 80, 81, 168), the more recent matrix-
mediated ACI (MACI) (169), or the grafting of tissue engineered cartilaginous constructs (TE) (170, 
171), typically based on cultivation of cells on porous scaffolds. 
 The main aim of my PhD was to study different aspects of human articular chondrocytes (HAC) 
biology and to evaluate their relevance for the generation of a tissue engineered construct with 
properties compatible with utilization in clinical cartilage repair. 
 
Study 1 
Main results 
In the first study we showed that the use of the specific growth factor combination TGFβ-1/FGF-
2/PDGF (TFP) during the expansion of human articular chondrocytes (HAC) allows to obtain (i) a 
clinically relevant number of competent cells also if initially seeded at low densities (and therefore 
starting from a cartilage biopsy of small size), (ii) reduced variability in proliferation and cartilage 
forming capacity of cells expanded under different conditions of seeding densities  and human serum 
percentages. 
Relevance 
Cartilage biopsies are variable in size while harvesting an excess of it is a detrimental loss that 
should be minimized. Consequently, the number of chondrocytes obtainable from a biopsy is variable 
Summary & Conclusion 
83 
and relatively low for a clinical application. In addition, the final cell-based products vary in size 
according to the needs of individual patients (79). Therefore, the monolayer expansion, which is the 
core process of all the above mentioned cell-based techniques, is affected by these variables, resulting 
in low reproducibility.  
Moreover, in the last years, efforts to commercialize cell-based therapies are raising the need 
for capable, reproducible, scalable, automated manufacturing systems. 
The use of bioreactors within the hospital for automated culture of autologous cells would eliminate 
logistical issues of transferring specimens between locations, reduce the need for large and expensive 
GMP facilities and minimize operator handling with the final possible result of simplifying, reducing 
the cost and increasing the standardization of the entire process (166, 167).  
In our study we have defined culture conditions allowing to overcome some constraints related to the 
implementation of closed automated bioreactor system for the generation of implantable autologous 
cartilage products in which the cells isolable from cartilage biopsies of different sizes have to be 
expanded in only one passage on a fixed culture surface. Moreover, the system should use human 
autologous serum at low percentages, to avoid use of animal derived factors and to reduce the 
dependence of the culture on a non-standardized factor such as autologous serum. 
The concept of using specific growth factors in clinical-grade bioreactors could be applied for 
the propagation of cells from different human sources to reduce variability in the number and quality 
of expanded cells and, ultimately, in the clinical outcome of cell-based regenerative techniques. 
 
Study 2 
Main results 
In this study we demonstrated that expansion of freshly isolated HAC, in biomimetic three-
dimensional scaffold (type II collagen sponge), as compared to expansion in monolayer, better 
maintains the chondrocytic phenotype but does not enhance the cartilage-forming capacity of HAC. 
Instead, increasing the HAC seeding density in the scaffolds allowed enhanced chondrogenesis, even 
if the seeded cells had to be expanded more extensively in 2D in order to reach the required cell 
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numbers. Therefore, high seeding density of HAC in 3D scaffolds is more critical for the generation of 
cartilaginous constructs than the stage of cell differentiation reached following expansion. 
Relevance 
Study 2 
Main results 
In this study we demonstrated that expansion of freshly isolated HAC in a biomimetic three-
dimensional scaffold (type II collagen sponge), as compared to expansion in monolayer, better 
maintain the chondrocytic phenotype but does not enhance the cartilage-forming capacity. Instead, 
increasing the HAC seeding density in the scaffolds allowed enhanced chondrogenesis, even if the 
seeded cells had to be expanded more extensively in 2D in order to reach the required cell numbers. 
Therefore, high seeding density of HAC in 3D scaffolds is proposed to be more critical for the 
generation of cartilaginous constructs than the stage of cell differentiation reached following 
expansion. 
Relevance 
Monolayer expansion, the core process of cell-based cartilage repair techniques is associated 
with cell de-differentiation and loss of the chondrocytic phenotype. Therefore to overcome the 
limitations of a low initial number of cells and dedifferentiation, various studies have been performed 
in which chondrocytes are multiplied in monolayer cultures to increase the number of cells and then 
transferred at high density to a long term three dimensional culture system to regain their phenotype 
(172, 173). An alternative strategy for the utilization of the small number of chondrocytes obtained 
from a cartilage biopsy consists in their limited expansion in 2D or even in the direct culture onto 3D 
porous scaffolds (174-176). In principle, this technique would allow a better maintenance of the 
chondrocytic phenotype while reducing the extent of cell proliferation and thus the cell seeding 
density. 
We showed that the extensively dedifferentiated phenotype of chondrocytes did not appear to 
interfere with the chondrogenic program, provided that high cell density was initially established. 
Indeed, the extent of HAC passaging and consequent stage of de-differentiation did not modify the 
cartilage-forming capacity of these cells following 3D culture. This is a further proof of the extensive 
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plasticity exhibited by HAC expanded in culture under suitable conditions (109, 147). Moreover our 
results clearly indicate that a high seeding density of HAC in 3D scaffolds is more critical for the 
generation of implantable cartilaginous constructs than the stage of cell differentiation reached 
following expansion.    
 
Study 3 
Main results 
In this study, we demonstrated that the profile of chemokine production and the response to 
inflammatory/degradative stimuli by monolayer expanded HAC correlated with the differentiation 
stage of cells cultured in micromass pellets. In particular, cells within more mature tissues produced 
higher amounts of the pro-inflammatory chemokines IL-8 and MCP-1 and releases lower amounts of 
MMPs following IL-1β stimulation. 
Relevance 
Expanded chondrocytes exhibit enhanced expression of de-differentiated markers (e.g.: versican, type 
I collagen and cathepsin B) as compared to native normal chondrocytes (108, 149, 151, 177). 
Moreover, it has been reported that, similarly to OA chondrocytes, ex-vivo cultured chondrocytes 
express a variety of pro-inflammatory chemokines/chemokine receptors and cartilage degenerative 
enzymes (178-183), whose production is enhanced by increasing cell passaging and by stimulation 
with IL-1β and TNF-α (184, 185). These responses have particular relevance in the context of cell 
based-cartilage repair, considering that therapeutic cell preparations (single cell suspension, cell-
seeded matrixes or cartilaginous tissues) once grafted in the joint defect will become exposed to a 
biochemical environment rich in catabolic mediators. The cell preparation in which the chondrocytes 
are less susceptible to such mediators might guarantee superior clinical outcome. Our findings that 
chondrocytes embedded in a more abundant cartilaginous matrix release lower levels of pro-
inflammatory chemokines and exhibit less IL-1β-mediated catabolic effects suggest that the 
implantation of more mature cartilaginous tissues could guarantee superior graft survival and 
functional outcome.  
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CONCLUSION 
In conclusion, during my PhD we demonstrated that the phenotype of human articular chondrocytes 
can be strongly modulated following the exposure to specific biological and physicochemical cues. 
The findings described in this work have therefore allowed to improve the knowledge on the biology 
of cartilage cells and to define specific conditions to improve the efficiency of utilization of 
chondrocytes for clinical applications.  
My findings resulted indeed essential in the definition of the culture conditions to use in a recently 
proposed internal phase I, prospective, uncontrolled clinical trial aimed at demonstrating safety and 
feasibility in the use of engineered cartilage grafts. The specific surgical target of the trial is the 
reconstruction of a two layer defect of the alar lobule using a tissue engineered nasal cartilage graft 
and a local flap, following resection of a nonmelanoma skin cancer. 
For such trial, in fact, nasal articular chondrocytes isolated from a small cartilage biopsy in the 
nose will be expanded in monolayer with medium containing low percentage of autologous serum and 
with the previously described growth factor combination (study 1). Cells will be then seeded at high 
density onto collagenous matrices (study 2) and cultured under differentiation conditions allowing to 
generate mature cartilage graft (study 3). 
 
During my PhD I worked in a unique environment where the scientific approach, clinical and industry 
point of views were combined in order to facilitate the achievement of a final and common goal. 
Indeed the interaction with different collaborating partners (i.e., the company Millenium Biologix AG 
and orthopaedic surgeons) helped me to remain focused on investigating scientific relevant questions 
which could bring to a final cell-based product, pertinent for a clinical application.  
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